Synthesis of Self-Assembled Nanostructured Cisplatin Using the RESS Process

Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. Method: In this context, we report the use of a customized RESS process for the synthesis of a...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 16; no. 11; p. 1471
Main Authors Sharma, Sudhir Kumar, Palanikumar, Loganathan, Pasricha, Renu, Prakasam, Thirumurugan, Magzoub, Mazin, Jagannathan, Ramesh
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.11.2024
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. Method: In this context, we report the use of a customized RESS process for the synthesis of a novel, amber-colored and viscous aqueous cisplatin solution, an important anticancer drug, which we have denoted as “liquid” cisplatin. Results: Using specialized liquid cell in situ transmission electron microscopy (Liquid in situ TEM) and Raman spectroscopy, we demonstrated that “liquid” cisplatin comprises a bi-modal distribution of a highly solvated network of stable cisplatin nanoclusters in water and exhibited 27 times greater water solubility than standard cisplatin. More importantly, “liquid” cisplatin was stable at ambient conditions for over two years. Extensive analytical characterization of “liquid” cisplatin confirmed that it retained the original chemical identity of cisplatin. Cell viability and apoptosis studies on human lung adenocarcinoma A549 cells provided compelling evidence that “liquid” cisplatin demonstrated a more sustained anticancer effect compared to standard cisplatin. Conclusions: Aqueous cisplatin solubility was increased by 27X in the “liquid” cisplatin medium which retained its bio efficacy over a 2-year period. Our experimental results suggest the possibility of developing non-invasive and highly effective novel cisplatin drug-delivery platforms.
AbstractList The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. In this context, we report the use of a customized RESS process for the synthesis of a novel, amber-colored and viscous aqueous cisplatin solution, an important anticancer drug, which we have denoted as "liquid" cisplatin. Using specialized liquid cell in situ transmission electron microscopy (Liquid in situ TEM) and Raman spectroscopy, we demonstrated that "liquid" cisplatin comprises a bi-modal distribution of a highly solvated network of stable cisplatin nanoclusters in water and exhibited 27 times greater water solubility than standard cisplatin. More importantly, "liquid" cisplatin was stable at ambient conditions for over two years. Extensive analytical characterization of "liquid" cisplatin confirmed that it retained the original chemical identity of cisplatin. Cell viability and apoptosis studies on human lung adenocarcinoma A549 cells provided compelling evidence that "liquid" cisplatin demonstrated a more sustained anticancer effect compared to standard cisplatin. Aqueous cisplatin solubility was increased by 27X in the "liquid" cisplatin medium which retained its bio efficacy over a 2-year period. Our experimental results suggest the possibility of developing non-invasive and highly effective novel cisplatin drug-delivery platforms.
Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. Method: In this context, we report the use of a customized RESS process for the synthesis of a novel, amber-colored and viscous aqueous cisplatin solution, an important anticancer drug, which we have denoted as "liquid" cisplatin. Results: Using specialized liquid cell in situ transmission electron microscopy (Liquid in situ TEM) and Raman spectroscopy, we demonstrated that "liquid" cisplatin comprises a bi-modal distribution of a highly solvated network of stable cisplatin nanoclusters in water and exhibited 27 times greater water solubility than standard cisplatin. More importantly, "liquid" cisplatin was stable at ambient conditions for over two years. Extensive analytical characterization of "liquid" cisplatin confirmed that it retained the original chemical identity of cisplatin. Cell viability and apoptosis studies on human lung adenocarcinoma A549 cells provided compelling evidence that "liquid" cisplatin demonstrated a more sustained anticancer effect compared to standard cisplatin. Conclusions: Aqueous cisplatin solubility was increased by 27X in the "liquid" cisplatin medium which retained its bio efficacy over a 2-year period. Our experimental results suggest the possibility of developing non-invasive and highly effective novel cisplatin drug-delivery platforms.Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. Method: In this context, we report the use of a customized RESS process for the synthesis of a novel, amber-colored and viscous aqueous cisplatin solution, an important anticancer drug, which we have denoted as "liquid" cisplatin. Results: Using specialized liquid cell in situ transmission electron microscopy (Liquid in situ TEM) and Raman spectroscopy, we demonstrated that "liquid" cisplatin comprises a bi-modal distribution of a highly solvated network of stable cisplatin nanoclusters in water and exhibited 27 times greater water solubility than standard cisplatin. More importantly, "liquid" cisplatin was stable at ambient conditions for over two years. Extensive analytical characterization of "liquid" cisplatin confirmed that it retained the original chemical identity of cisplatin. Cell viability and apoptosis studies on human lung adenocarcinoma A549 cells provided compelling evidence that "liquid" cisplatin demonstrated a more sustained anticancer effect compared to standard cisplatin. Conclusions: Aqueous cisplatin solubility was increased by 27X in the "liquid" cisplatin medium which retained its bio efficacy over a 2-year period. Our experimental results suggest the possibility of developing non-invasive and highly effective novel cisplatin drug-delivery platforms.
Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. Method: In this context, we report the use of a customized RESS process for the synthesis of a novel, amber-colored and viscous aqueous cisplatin solution, an important anticancer drug, which we have denoted as “liquid” cisplatin. Results: Using specialized liquid cell in situ transmission electron microscopy (Liquid in situ TEM) and Raman spectroscopy, we demonstrated that “liquid” cisplatin comprises a bi-modal distribution of a highly solvated network of stable cisplatin nanoclusters in water and exhibited 27 times greater water solubility than standard cisplatin. More importantly, “liquid” cisplatin was stable at ambient conditions for over two years. Extensive analytical characterization of “liquid” cisplatin confirmed that it retained the original chemical identity of cisplatin. Cell viability and apoptosis studies on human lung adenocarcinoma A549 cells provided compelling evidence that “liquid” cisplatin demonstrated a more sustained anticancer effect compared to standard cisplatin. Conclusions: Aqueous cisplatin solubility was increased by 27X in the “liquid” cisplatin medium which retained its bio efficacy over a 2-year period. Our experimental results suggest the possibility of developing non-invasive and highly effective novel cisplatin drug-delivery platforms.
Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. Method: In this context, we report the use of a customized RESS process for the synthesis of a novel, amber-colored and viscous aqueous cisplatin solution, an important anticancer drug, which we have denoted as “liquid” cisplatin. Results: Using specialized liquid cell in situ transmission electron microscopy (Liquid in situ TEM) and Raman spectroscopy, we demonstrated that “liquid” cisplatin comprises a bi-modal distribution of a highly solvated network of stable cisplatin nanoclusters in water and exhibited 27 times greater water solubility than standard cisplatin. More importantly, “liquid” cisplatin was stable at ambient conditions for over two years. Extensive analytical characterization of “liquid” cisplatin confirmed that it retained the original chemical identity of cisplatin. Cell viability and apoptosis studies on human lung adenocarcinoma A549 cells provided compelling evidence that “liquid” cisplatin demonstrated a more sustained anticancer effect compared to standard cisplatin. Conclusions: Aqueous cisplatin solubility was increased by 27X in the “liquid” cisplatin medium which retained its bio efficacy over a 2-year period. Our experimental results suggest the possibility of developing non-invasive and highly effective novel cisplatin drug-delivery platforms.
Audience Academic
Author Prakasam, Thirumurugan
Palanikumar, Loganathan
Jagannathan, Ramesh
Sharma, Sudhir Kumar
Pasricha, Renu
Magzoub, Mazin
AuthorAffiliation 3 Retired from Core Technology Platform, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; renu1505@gmail.com
1 Engineering Division, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; sks16@nyu.edu
4 Science Division, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; tp42@nyu.edu
2 Biology Program, Division of Science, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; pl105@nyu.edu (L.P.); mm6432@nyu.edu (M.M.)
AuthorAffiliation_xml – name: 2 Biology Program, Division of Science, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; pl105@nyu.edu (L.P.); mm6432@nyu.edu (M.M.)
– name: 3 Retired from Core Technology Platform, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; renu1505@gmail.com
– name: 4 Science Division, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; tp42@nyu.edu
– name: 1 Engineering Division, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; sks16@nyu.edu
Author_xml – sequence: 1
  givenname: Sudhir Kumar
  surname: Sharma
  fullname: Sharma, Sudhir Kumar
– sequence: 2
  givenname: Loganathan
  surname: Palanikumar
  fullname: Palanikumar, Loganathan
– sequence: 3
  givenname: Renu
  surname: Pasricha
  fullname: Pasricha, Renu
– sequence: 4
  givenname: Thirumurugan
  orcidid: 0000-0003-3450-6328
  surname: Prakasam
  fullname: Prakasam, Thirumurugan
– sequence: 5
  givenname: Mazin
  orcidid: 0000-0003-3414-6617
  surname: Magzoub
  fullname: Magzoub, Mazin
– sequence: 6
  givenname: Ramesh
  orcidid: 0000-0003-0269-6446
  surname: Jagannathan
  fullname: Jagannathan, Ramesh
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39598594$$D View this record in MEDLINE/PubMed
BookMark eNptkltvFCEUgImpsRf7EzST-OLLVhhgBp7MZlNrY6PGtc8EmMMumxlYYcak_162W2vXFB64fecj5-ScoqMQAyD0huALSiX-sF3rNGgL0-htJg0hhLXkBTohUsoZkzU9erI_Ruc5b3AZlBJB5St0TCWXgkt2gr4s78K4huxzFV21hN7N5jnDYHroqq86xDymyY5TKseFz9tejz5Ut9mHVVXiqh-Xy2X1PUULOb9GL53uM5w_rGfo9tPlz8Xn2c23q-vF_GZmeU3GmdZdJ7jATeOMtqxlrcOUa8lb6nSrNSW8rS0Fo7npnHG1NM7xxkoJzgBgeoau994u6o3aJj_odKei9ur-IqaV0qlUpgcFxUsayqwFxiwRBhOKO8MlcC4c7orr4961ncwAnYUwJt0fSA9fgl-rVfytCOGybbkshvcPhhR_TZBHNfhsoe91gDhlRQmljEvc8IK--w_dxCmFUqt7qm5kU4t_1EqXDHxwsXxsd1I1F0SwRhCyoy6eocrsYPC2tIvz5f4g4O3TTB9T_NsLBeB7wKaYcwL3iBCsdm2nnm07-gfHF82w
Cites_doi 10.1182/blood.V84.5.1415.bloodjournal8451415
10.1016/j.supflu.2015.11.019
10.1038/s41467-021-23985-1
10.1002/ijc.33588
10.1074/jbc.M109.026583
10.1111/cbdd.12786
10.1021/acsomega.7b00688
10.5114/wo.2012.31775
10.3322/caac.21763
10.1039/C9NA00684B
10.1038/377580a0
10.1200/JCO.2011.39.1110
10.1038/nrc2167
10.1002/9780470405840
10.1080/01926230701320337
10.4103/0253-7613.157132
10.1016/S0960-894X(01)81162-8
10.1016/j.phrs.2016.01.001
10.3322/caac.21731
10.1021/acs.biochem.0c00141
10.1016/S0896-8446(01)00064-X
10.1038/s42003-020-0817-4
10.1016/j.jddst.2022.103928
10.1126/science.6890712
10.1021/acsomega.9b03917
10.1006/abbi.1993.1311
10.1186/s40780-020-00163-x
10.1007/s00374-014-0940-9
10.1016/j.bioorg.2019.102925
10.1021/acsnano.3c04564
10.1016/j.ejphar.2014.07.025
10.1016/j.jinorgbio.2015.09.002
10.1016/j.apsusc.2013.05.159
10.1021/acs.jpca.8b04023
10.1007/s11095-013-1134-0
10.3892/or.2013.2279
ContentType Journal Article
Copyright COPYRIGHT 2024 MDPI AG
2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2024 by the authors. 2024
Copyright_xml – notice: COPYRIGHT 2024 MDPI AG
– notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2024 by the authors. 2024
DBID AAYXX
CITATION
NPM
3V.
7XB
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
GNUQQ
GUQSH
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3390/pharmaceutics16111471
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
ProQuest Central Student
ProQuest Research Library
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Basic
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Academic UKI Edition
ProQuest Central Korea
ProQuest Research Library
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Publicly Available Content Database

CrossRef


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1999-4923
ExternalDocumentID oai_doaj_org_article_e5a91634cce44c18b0130db59e558f0d
PMC11597759
A818468118
39598594
10_3390_pharmaceutics16111471
Genre Journal Article
GeographicLocations United States
United Arab Emirates
GeographicLocations_xml – name: United Arab Emirates
– name: United States
GrantInformation_xml – fundername: NYU Abu Dhabi
  grantid: AD008; AD389
GroupedDBID ---
53G
5VS
8G5
AADQD
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACUHS
AEAQA
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BENPR
BPHCQ
CCPQU
CITATION
DIK
DWQXO
EBD
ESX
F5P
FD6
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HH5
HYE
IAO
IHR
ITC
KQ8
M2O
M48
MK0
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
TR2
TUS
3V.
NPM
PMFND
7XB
8FK
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c521t-aadd858066fbac4747f035a9573fa7aa31572c3eba5bdfbf29bff56c99efbee03
IEDL.DBID M48
ISSN 1999-4923
IngestDate Wed Aug 27 01:32:15 EDT 2025
Thu Aug 21 18:34:57 EDT 2025
Fri Jul 11 05:12:58 EDT 2025
Mon Jun 30 14:02:55 EDT 2025
Tue Jun 17 21:56:07 EDT 2025
Tue Jun 10 21:04:29 EDT 2025
Wed Feb 19 02:03:56 EST 2025
Tue Jul 01 00:37:18 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords liquid in situ transmission electron microscopy
supercritical CO2 processing
apoptosis
RESS technique
cell viability
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c521t-aadd858066fbac4747f035a9573fa7aa31572c3eba5bdfbf29bff56c99efbee03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-0269-6446
0000-0003-3414-6617
0000-0003-3450-6328
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/pharmaceutics16111471
PMID 39598594
PQID 3133269628
PQPubID 2032349
ParticipantIDs doaj_primary_oai_doaj_org_article_e5a91634cce44c18b0130db59e558f0d
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11597759
proquest_miscellaneous_3133459065
proquest_journals_3133269628
gale_infotracmisc_A818468118
gale_infotracacademiconefile_A818468118
pubmed_primary_39598594
crossref_primary_10_3390_pharmaceutics16111471
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-11-01
PublicationDateYYYYMMDD 2024-11-01
PublicationDate_xml – month: 11
  year: 2024
  text: 2024-11-01
  day: 01
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Pharmaceutics
PublicationTitleAlternate Pharmaceutics
PublicationYear 2024
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Tardito (ref_40) 2009; 284
Araujo (ref_31) 2014; 50
Tuschel (ref_32) 2014; 29
Pourmadadi (ref_12) 2022; 77
ref_34
Kelland (ref_5) 2007; 7
Brown (ref_8) 2019; 11
Palanikumar (ref_29) 2021; 12
Raghavan (ref_15) 2015; 47
Karbownik (ref_18) 2012; 16
Torres (ref_36) 2018; 122
Greene (ref_17) 1979; 36
ref_16
Kumar (ref_39) 2017; 2
Dasari (ref_9) 2014; 740
Jung (ref_20) 2001; 20
Sharma (ref_19) 2016; 109
Parhizkar (ref_37) 2020; 2
Koopman (ref_27) 1994; 84
Abe (ref_14) 2020; 6
Berridge (ref_24) 1993; 303
Palanikumar (ref_25) 2020; 59
Petsko (ref_4) 1995; 377
Amable (ref_10) 2016; 106
Brock (ref_11) 2012; 30
Sharma (ref_22) 2013; 282
Palanikumar (ref_30) 2023; 17
Ferlay (ref_1) 2021; 149
Astolfi (ref_13) 2013; 29
Siegel (ref_2) 2023; 73
ref_28
Elmore (ref_26) 2007; 35
Miller (ref_3) 2022; 72
Sharma (ref_21) 2020; 5
Munaweera (ref_33) 2015; 153
Barltrop (ref_23) 1991; 1
ref_7
Li (ref_38) 2014; 31
Lippard (ref_6) 1982; 218
Poy (ref_35) 2016; 88
References_xml – volume: 36
  start-page: 38
  year: 1979
  ident: ref_17
  article-title: Stability of Cisplatin in Aqueous Solution
  publication-title: Am. J. Hosp. Pharm.
– volume: 84
  start-page: 1415
  year: 1994
  ident: ref_27
  article-title: Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis
  publication-title: Blood
  doi: 10.1182/blood.V84.5.1415.bloodjournal8451415
– volume: 109
  start-page: 74
  year: 2016
  ident: ref_19
  article-title: High Throughput RESS Processing of Sub-10nm Ibuprofen Nanoparticles
  publication-title: J. Supercrit. Fluids
  doi: 10.1016/j.supflu.2015.11.019
– volume: 12
  start-page: 3962
  year: 2021
  ident: ref_29
  article-title: Protein Mimetic Amyloid Inhibitor Potently Abrogates Cancer-Associated Mutant P53 Aggregation and Restores Tumor Suppressor Function
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-23985-1
– volume: 149
  start-page: 778
  year: 2021
  ident: ref_1
  article-title: Cancer Statistics for the Year 2020: An Overview
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.33588
– volume: 284
  start-page: 24306
  year: 2009
  ident: ref_40
  article-title: The Thioxotriazole Copper (II) Complex A0 Induces Endoplasmic Reticulum Stress and Paraptotic Death in Human Cancer Cells
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M109.026583
– ident: ref_16
– volume: 88
  start-page: 568
  year: 2016
  ident: ref_35
  article-title: Preparation, Characterization, and Cytotoxic Effects of Liposomal Nanoparticles Containing Cisplatin: An in Vitro Study
  publication-title: Chem. Biol. Drug Des.
  doi: 10.1111/cbdd.12786
– volume: 2
  start-page: 4632
  year: 2017
  ident: ref_39
  article-title: Potent Anticancer Activity with High Selectivity of a Chiral Palladium N-Heterocyclic Carbene Complex
  publication-title: ACS Omega
  doi: 10.1021/acsomega.7b00688
– volume: 16
  start-page: 435
  year: 2012
  ident: ref_18
  article-title: The Physical and Chemical Stability of Cisplatin (Teva) in Concentrate and Diluted in Sodium Chloride 0.9%
  publication-title: Wspolczesna Onkol.
  doi: 10.5114/wo.2012.31775
– volume: 29
  start-page: 14
  year: 2014
  ident: ref_32
  article-title: Practical Group Theory and Raman Spectroscopy, Part I: Normal Vibrational Modes
  publication-title: Spectroscopy
– volume: 73
  start-page: 17
  year: 2023
  ident: ref_2
  article-title: Cancer Statistics, 2023
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21763
– volume: 2
  start-page: 1177
  year: 2020
  ident: ref_37
  article-title: Enhanced Efficacy in Drug-Resistant Cancer Cells through Synergistic Nanoparticle Mediated Delivery of Cisplatin and Decitabine
  publication-title: Nanoscale Adv.
  doi: 10.1039/C9NA00684B
– volume: 377
  start-page: 580
  year: 1995
  ident: ref_4
  article-title: Heavy Metal Revival
  publication-title: Nature
  doi: 10.1038/377580a0
– volume: 30
  start-page: 2408
  year: 2012
  ident: ref_11
  article-title: Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2011.39.1110
– volume: 7
  start-page: 573
  year: 2007
  ident: ref_5
  article-title: The Resurgence of Platinum-Based Cancer Chemotherapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2167
– ident: ref_34
  doi: 10.1002/9780470405840
– volume: 35
  start-page: 495
  year: 2007
  ident: ref_26
  article-title: Apoptosis: A Review of Programmed Cell Death
  publication-title: Toxicol. Pathol.
  doi: 10.1080/01926230701320337
– volume: 47
  start-page: 322
  year: 2015
  ident: ref_15
  article-title: Dimethyl Sulfoxide Inactivates the Anticancer Effect of Cisplatin against Human Myelogenous Leukemia Cell Lines in in Vitro Assays
  publication-title: Indian J. Pharmacol.
  doi: 10.4103/0253-7613.157132
– volume: 1
  start-page: 611
  year: 1991
  ident: ref_23
  article-title: 5-(3-Carboxymethoxyphenyl)-2-(4,5-Dimethylthiazolyl)-3-(4-Sulfophenyl)Te Trazolium, Inner Salt (MTS) and Related Analogs of 3-(4,5-Dimethylthiazolyl)-2,5-Diphenyltetrazolium Bromide (MTT) Reducing to Purple Water-Soluble Formazans As Cell-Viability Indica
  publication-title: Bioorganic Med. Chem. Lett.
  doi: 10.1016/S0960-894X(01)81162-8
– volume: 106
  start-page: 27
  year: 2016
  ident: ref_10
  article-title: Cisplatin Resistance and Opportunities for Precision Medicine
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2016.01.001
– volume: 72
  start-page: 409
  year: 2022
  ident: ref_3
  article-title: Cancer Treatment and Survivorship Statistics, 2022
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21731
– volume: 59
  start-page: 2259
  year: 2020
  ident: ref_25
  article-title: Hexokinase II-Derived Cell-Penetrating Peptide Mediates Delivery of MicroRNA Mimic for Cancer-Selective Cytotoxicity
  publication-title: Biochemistry
  doi: 10.1021/acs.biochem.0c00141
– volume: 20
  start-page: 179
  year: 2001
  ident: ref_20
  article-title: Particle Design Using Supercritical Fluids: Literature and Patent Survey
  publication-title: J. Supercrit. Fluids
  doi: 10.1016/S0896-8446(01)00064-X
– ident: ref_28
  doi: 10.1038/s42003-020-0817-4
– volume: 77
  start-page: 103928
  year: 2022
  ident: ref_12
  article-title: Cisplatin-Loaded Nanoformulations for Cancer Therapy: A Comprehensive Review
  publication-title: J. Drug Deliv. Sci. Technol.
  doi: 10.1016/j.jddst.2022.103928
– volume: 218
  start-page: 1075
  year: 1982
  ident: ref_6
  article-title: New Chemistry of an Old Molecule: Cis-[Pt(NH3) 2Cl2]
  publication-title: Science
  doi: 10.1126/science.6890712
– volume: 5
  start-page: 4558
  year: 2020
  ident: ref_21
  article-title: Supercritical CO2 Processing Generates Aqueous Cisplatin Solutions with Enhanced Cancer Specificity
  publication-title: ACS Omega
  doi: 10.1021/acsomega.9b03917
– volume: 303
  start-page: 474
  year: 1993
  ident: ref_24
  article-title: Characterization of the Cellular Reduction of 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT): Subcellular Localization, Substrate Dependence, and Involvement of Mitochondrial Electron Transport in MTT Reduction
  publication-title: Arch. Biochem. Biophys.
  doi: 10.1006/abbi.1993.1311
– volume: 6
  start-page: 3
  year: 2020
  ident: ref_14
  article-title: Effect of Different Shielding Conditions on the Stability of Cisplatin
  publication-title: J. Pharm. Health Care Sci.
  doi: 10.1186/s40780-020-00163-x
– volume: 50
  start-page: 1223
  year: 2014
  ident: ref_31
  article-title: Selective Extraction of Humic Acids from an Anthropogenic Amazonian Dark Earth and from a Chemically Oxidized Charcoal
  publication-title: Biol. Fertil. Soils
  doi: 10.1007/s00374-014-0940-9
– ident: ref_7
  doi: 10.1016/j.bioorg.2019.102925
– volume: 17
  start-page: 18979
  year: 2023
  ident: ref_30
  article-title: PH-Responsive Upconversion Mesoporous Silica Nanospheres for Combined Multimodal Diagnostic Imaging and Targeted Photodynamic and Photothermal Cancer Therapy
  publication-title: ACS Nano
  doi: 10.1021/acsnano.3c04564
– volume: 740
  start-page: 364
  year: 2014
  ident: ref_9
  article-title: Cisplatin in Cancer Therapy: Molecular Mechanisms of Action
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2014.07.025
– volume: 153
  start-page: 23
  year: 2015
  ident: ref_33
  article-title: Nitric Oxide- and Cisplatin-Releasing Silica Nanoparticles for Use against Non-Small Cell Lung Cancer
  publication-title: J. Inorg. Biochem.
  doi: 10.1016/j.jinorgbio.2015.09.002
– volume: 282
  start-page: 492
  year: 2013
  ident: ref_22
  article-title: Influence of Annealing on Structural, Morphological, Compositional and Surface Properties of Magnetron Sputtered Nickel-Titanium Thin Films
  publication-title: Appl. Surf. Sci.
  doi: 10.1016/j.apsusc.2013.05.159
– volume: 11
  start-page: 97
  year: 2019
  ident: ref_8
  article-title: Cisplatin-Based Chemotherapy of Human Cancers
  publication-title: J. Cancer Sci. Ther.
– volume: 122
  start-page: 6934
  year: 2018
  ident: ref_36
  article-title: Raman and Infrared Studies of Platinum-Based Drugs: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, and Heptaplatin
  publication-title: J. Phys. Chem. A
  doi: 10.1021/acs.jpca.8b04023
– volume: 31
  start-page: 86
  year: 2014
  ident: ref_38
  article-title: Pharmacological Modulation of Cytotoxicity and Cellular Uptake of Anti-Cancer Drugs by PDE5 Inhibitors in Lung Cancer Cells
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-013-1134-0
– volume: 29
  start-page: 1285
  year: 2013
  ident: ref_13
  article-title: Correlation of Adverse Effects of Cisplatin Administration in Patients Affected by Solid Tumours: A Retrospective Evaluation
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2013.2279
SSID ssj0000331839
Score 2.3286483
Snippet Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug,...
The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility...
Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug,...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1471
SubjectTerms apoptosis
Cancer
Cancer therapies
Carbon dioxide
Care and treatment
Cell research
cell viability
Cisplatin
Cytotoxicity
Drug delivery systems
Ethylenediaminetetraacetic acid
Leukemia
liquid in situ transmission electron microscopy
Raman spectroscopy
RESS technique
Side effects
supercritical CO2 processing
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYQJy4VfZIClStV9EJKEj9iHwGBUKsiJEDiZtmOLVaC7IqUw_57ZuKwu1GRuHBM7CjxPL9xZsaE_AiyArdS81yVUeRcNkVuIbTOZSNRphtfRSxO_nsuz6757xtxs3LUF-aEpfbAiXAHQVhAMIx7Hzj3pcJ9u6JxQgchVCwatL7g81aCqd4GM5RVnUp2GLz8YHa73CLuAOZAHFCXI2fU9-z_3zKvuKZx2uSKHzrdJO8GAEkP04e_J2uh_UD2LtJ75_v0allQ1e3TPXqx7E09_0j-XM5bgHzdpKPTSC_DXczxt--9uwsNBUs7Tf1kHx_g8njSzTBTrqV9XgGF5yjyiw7FBZ_I9enJ1fFZPpynkHs8tiC3YMuUUAAyorOeQyARCwbkFTWLtraWlaKuPAvOCtdEFyvtYhTSax2iC6Fgn8l6O23DFqGxkM47QOfg_3mMXgXQZcYVZmE3umQZ-fVMWDNLbTMMhBvICfMiJzJyhORfTMau1_0NkAUzyIJ5TRYy8hOZZ1A3gUPeDiUG8M3Y5cocAjrhUkFMlZGd0UzQKT8efma_GXS6M7BAwLpaVjD8fTGMT2KeWhumj2kOFxpwXUa-JGlZLIlpoZXQPCNqJEejNY9H2slt3_EbYDvgdKG_vgWVtslGBcgsFVTukHWQq7ALyOqf-9Yr0RNAKSPs
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB61cOml6rsptHKlil5ISeLH2qcKEAi1KloVkLhFsWPDSjTZEjjsv-9M4t0latVjYkexPQ9_M54ZA3zyqsBtZSJSnQeZClVnaYWmdapqRTxduyJQcvKPU3VyIb5dysvocOtiWOVSJ_aKum4d-cj3OBpThTKq0F_nv1O6NYpOV-MVGo9hE1WwRuNr8-DodPpz5WXJOPGsGVJ3OA5ib369dhV3CHfQHpjko02pr93_t4Z-sEWNwycf7EfHz-BpBJJsf6D8c3jkmxewMx3-u9hl5-vEqm6X7bDpukb14iV8P1s0CP26WcfawM78TUjp-PeXvfE1Q43bDnVl72_x8XDWzSlirmF9fAHD7xjRjcUkg1dwcXx0fniSxnsVUkfXF6QV6jQtNYKNYCsn0KAIGZeVkRMeqklV8VxOCse9raStgw2FsSFI5YzxwXqf8dew0bSNfwssZMo6iygdcYAIwWmPMs2Fpmjs2uQ8gS_LhS3nQ_mMEs0OokT5T0okcEDLv-pM1a_7F-3tVRmFqfQ4WMSRwjkvhMs1-XKz2krjpdQhqxP4TMQrSUaRQq6KqQY4Zqp2Ve4jShFKo22VwPaoJ8qWGzcvyV9G2e7KNScm8HHVTF9SvFrj2_uhj5AG8V0CbwZuWU2JG2m0NCIBPeKj0ZzHLc3suq_8jfAd8bo07_4_ri14UiD2GlImt2EDOca_R-x0Zz9EAfkD_tYcxw
  priority: 102
  providerName: ProQuest
Title Synthesis of Self-Assembled Nanostructured Cisplatin Using the RESS Process
URI https://www.ncbi.nlm.nih.gov/pubmed/39598594
https://www.proquest.com/docview/3133269628
https://www.proquest.com/docview/3133459065
https://pubmed.ncbi.nlm.nih.gov/PMC11597759
https://doaj.org/article/e5a91634cce44c18b0130db59e558f0d
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dT9swED8heNnLtO9lY5WRJvZCWBrbif2AECAQ2gSqBpV4i2LHhkpd0jVDWv_73SVpSzR42GNiO7F9d77f2XdngM8uiVGtpCJUQy9DkRRRmKNpHSZFQjxd2NhTcPLFZXI-Ft9u5M0GLBMqdBNYP2ra0X1S4_l0_8-vxSEK_AFZnPjdr7O79e5vjQgGIT5FlW-hckpJVi86xN8szpyYWDdnzZruV4t5G9fz9Jd6GqtJ7P_v8v1Af_V9Kx8oq7MX8LxDmeyoZYuXsOHKV7A7av-72GPX66ireo_tstE6gfXiNXy_WpSIC-tJzSrPrtzUh3Q2_NNMXcFwOa7apLP3c3w8mdQzcqcrWeN8wLAdI6KyLgLhDYzPTq9PzsPu0oXQ0t0GYY4LnpIKkYg3uRVobfiIy1zLlPs8zXM-lGlsuTO5NIU3PtbGe5lYrZ03zkX8LWyWVeneA_NRYqxBCI8gQXhvlUOB50KRq3ahhzyA_eXEZrM2t0aGNglRInuUEgEc0_SvKlNq7OZFNb_NOknLHHYWQaaw1glhh4o2eqPCSO2kVD4qAvhCxMuIpZBCNu_iELDPlAorO0IIIxKFhlcA272aKHi2X7wkf7bk2wwHiIBYJzEW76yKqSU5s5Wuum_rCKkR_AXwruWW1ZC4llpJLQJQPT7qjblfUk7umrTgiO0RzEv94X-n9SM8ixGqtRGW27CJPOQ-IdT6bQawdXx6OfoxaLYqBo0o_QVqhSys
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFH8a3QEuiG8CA4wE47KwNLZT-4DQNjZ1dKsq1km7hdixWaWRlIUJ9Z_ib-S9Jm0XgbjtmNhJbL_Pn_PeM8Abl8RoVnoiVF0vQ5HkUZghtA6TPCGezm3sKTn5eJj0T8XnM3m2Br8XuTAUVrnQiXNFnZeW9si3OYKpONFJrD5Of4R0ahT9XV0coVGzxcDNfiFkqz4cfkL6vo3jg_3xXj9sThUILRXvDzOUaCUVmlpvMivQnfYRl5mWPe6zXpbxruzFljuTSZN742NtvJeJ1dp541zE8b23YF1whDIdWN_dH46-LHd1Ik4youtUIY6T3p6er7amK3SvEH_0ui0jOD8r4G-LcM0ktsM1r9m_g3twt3Fc2U7NafdhzRUPYHNUf3e2xcarRK5qi22y0aom9uwhDE5mBbqa1aRipWcn7sKH9Lv5u7lwOUMNX9Z1bK8u8XJvUk0pQq9g83gGhs8x4hPWJDU8gtMbWfHH0CnKwj0F5qPEWIOoAP0O4b1VDnUIF4qiv3Pd5QG8XyxsOq3LdaQIc4gS6T8pEcAuLf-yM1Xbnt8oL7-ljfCmDgeLfquw1glhu4r2jqPcSO2kVD7KA3hHxEtJJyCFbNakNuCYqbpWuoNekUgUYrkANlo9UZZtu3lB_rTRJVW64vwAXi-b6UmKjytceVX3EVKjPxnAk5pbllPiWmoltQhAtfioNed2SzE5n1caR7iA-EDqZ_8f1yu43R8fH6VHh8PBc7gTo99Xp2tuQAe5x71Av-2nedkIC4OvNy2ffwDPxVxy
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4anYR4QdwJDDASjJdlTWI7sR8Q2q3aKFQV26S9hdixWaWRlIUJ9a_x6zjOpV0E4m2PbZzW8bl9n3POMcAbE0cYVhLmi9Byn8V54GdIrf04j51O5zqyrjj58yQ-PGUfz_jZGvzuamFcWmXnE2tHnZfa7ZEPKZKpKJZxJIa2TYuY7o8-zH_47gQp96a1O06jUZGxWfxC-la9P9pHWb-NotHByd6h354w4GvXyN_P0LoFFxh2rco0Q2htA8ozyRNqsyTLaMiTSFOjMq5yq2wklbU81lIaq4wJKP7uLVhPkBUFA1jfPZhMvyx3eALq7EU2ZUMUF2A4P19tU1cItZCLJGEvINbnBvwdHa6Fx37q5rVYOLoHd1sQS3YarbsPa6Z4AJvT5n8XW-RkVdRVbZFNMl31x148hPHxokDYWc0qUlpybC6s7149f1cXJifo7cump-3VJX7cm1Vzl61XkDq3geB9xOkMaQscHsHpjaz4YxgUZWGeArFBrLRChoAYhFmrhUF_QplwmeC5DKkH293CpvOmdUeKlMdJIv2nJDzYdcu_HOw6b9dflJff0taQU4OTRQzLtDaM6VC4feQgV1wazoUNcg_eOeGlzj-ghHTWljngnF2nrXQHERKLBfI6DzZ6I9Gudf9yJ_609StVurICD14vL7s7Xa5cYcqrZgzjErGlB08abVk-EpVcCi6ZB6KnR71n7l8pZud113GkDsgVuHz2_3m9gttol-mno8n4OdyJEAI2lZsbMEDlMS8Qwv1UL1tbIfD1ps3zD6srYKc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synthesis+of+Self-Assembled+Nanostructured+Cisplatin+Using+the+RESS+Process&rft.jtitle=Pharmaceutics&rft.au=Sharma%2C+Sudhir+Kumar&rft.au=Palanikumar%2C+Loganathan&rft.au=Pasricha%2C+Renu&rft.au=Prakasam%2C+Thirumurugan&rft.date=2024-11-01&rft.issn=1999-4923&rft.eissn=1999-4923&rft.volume=16&rft.issue=11&rft.spage=1471&rft_id=info:doi/10.3390%2Fpharmaceutics16111471&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_pharmaceutics16111471
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4923&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4923&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4923&client=summon